tetano
Editor, Senior Moderator
Cell Signal
. 2020 Jul 22;109721.
doi: 10.1016/j.cellsig.2020.109721. Online ahead of print.
Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19
Ramarao Poduri[SUP] 1 [/SUP], Gaurav Joshi[SUP] 1 [/SUP], Gowraganahalli Jagadeesh[SUP] 2 [/SUP]
Affiliations
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense, single-stranded RNA virus that causes the potentially lethal Covid-19 respiratory tract infection. It does so by binding to host cell angiotensin converting enzyme 2 (ACE2) receptors, leading to endocytosis with the receptor, and subsequently using the host cell's machinery to replicate copies of itself and invade new cells. The extent of the spread of infection in the body is dependent on the pattern of ACE2 expression and overreaction of the immune system. Additionally, by inducing an imbalance in the renin-angiotensin-aldosterone system (RAAS) and the loss of ACE2 would favour the progression of inflammatory and thrombotic processes in the lungs. No drug or vaccine has yet been approved to treat human coronaviruses. Hundreds of clinical trials on existing approved drugs from different classes acting on a multitude of targets in the virus life cycle are ongoing to examine potential effectiveness for the prevention and treatment of the infection. This review summarizes the SARS-CoV-2 virus life cycle in the host cell and provides a biological and pathological point of view for repurposed and experimental drugs for this novel coronavirus. The viral lifecycle provides potential targets for drug therapy.
Keywords: ACE2; Ang (1-7); Covid-19; Immunomodulators; Remdesivir; SARS-CoV-2.
. 2020 Jul 22;109721.
doi: 10.1016/j.cellsig.2020.109721. Online ahead of print.
Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19
Ramarao Poduri[SUP] 1 [/SUP], Gaurav Joshi[SUP] 1 [/SUP], Gowraganahalli Jagadeesh[SUP] 2 [/SUP]
Affiliations
- PMID: 32711111
- DOI: 10.1016/j.cellsig.2020.109721
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense, single-stranded RNA virus that causes the potentially lethal Covid-19 respiratory tract infection. It does so by binding to host cell angiotensin converting enzyme 2 (ACE2) receptors, leading to endocytosis with the receptor, and subsequently using the host cell's machinery to replicate copies of itself and invade new cells. The extent of the spread of infection in the body is dependent on the pattern of ACE2 expression and overreaction of the immune system. Additionally, by inducing an imbalance in the renin-angiotensin-aldosterone system (RAAS) and the loss of ACE2 would favour the progression of inflammatory and thrombotic processes in the lungs. No drug or vaccine has yet been approved to treat human coronaviruses. Hundreds of clinical trials on existing approved drugs from different classes acting on a multitude of targets in the virus life cycle are ongoing to examine potential effectiveness for the prevention and treatment of the infection. This review summarizes the SARS-CoV-2 virus life cycle in the host cell and provides a biological and pathological point of view for repurposed and experimental drugs for this novel coronavirus. The viral lifecycle provides potential targets for drug therapy.
Keywords: ACE2; Ang (1-7); Covid-19; Immunomodulators; Remdesivir; SARS-CoV-2.